Matthew Scholz

Matthew Scholz is a serial biotechnology entrepreneur and executive who has established or co-founded five distinct biotechnology companies operating within the life sciences sector. Throughout his professional career, he has directed research and development for advanced therapeutics, resulting in the successful creation of three first-in-class treatment modalities. Scholz holds an interdisciplinary technical background that bridges early professional experience in computer security with extensive subsequent work in advanced gene therapy. As a researcher and inventor, he has authored dozens of patents covering novel transfection technologies, immune cell programming, and the in vivo production of therapeutic proteins. His broader intellectual property portfolio also includes specific applications for age-related cellular degradation and targeted cancer treatments. Scholz currently focuses his therapeutics development efforts on advancing new biotechnology platforms within the specialized medical fields of senolytics, human longevity, and oncology.